Is ARQT a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Multi-indication ZORYVE expansion, with 2026 revenue guidance at ~$480-495 million. The bear case rests on the dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. Analysts covering it are spread from $33.00 to $36.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $33.00, +17.5% from the $28.09 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Multi-indication ZORYVE expansion. ZORYVE has moved from a single plaque-psoriasis cream to a franchise spanning psoriasis, seborrheic dermatitis, and atopic dermatitis across creams and a foam. The most optimistic analyst target on ARQT is $36.00, +28.2% from the $28.09 price. That figure is only reachable if this thesis works close to its best case.

The dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. Profitability is early and inconsistent, with Q1 2026 returning to a small loss on seasonality and reinvestment, and the business carries a large accumulated deficit built up over its pre-commercial years. Competition is real, including Incyte's Opzelura (a JAK-inhibitor cream), Dermavant's Vtama (tapinarof), generic topical steroids, and systemic biologics like Dupixent in atopic dermatitis. Gross-to-net adjustments, rebates, and inventory timing can make quarterly revenue lumpy, and continued sales-force and marketing spend can keep operating results volatile even as demand grows. The most pessimistic published target is $33.00, +17.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on medical dermatology.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Multi-indication ZORYVE expansion) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Arcutis is a commercial-stage medical dermatology company. Its business centers on ZORYVE, a topical roflumilast (PDE4 inhibitor) sold as creams and a foam approved for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis across a range of ages.

ZORYVE is Arcutis's flagship product and the source of essentially all its revenue. It is a steroid-free, once-daily topical PDE4 inhibitor that the company markets as the leading branded topical across three inflammatory skin conditions, so ARQT's results track ZORYVE prescriptions closely.

Arcutis reached its first profitable quarter in Q4 2025 (about $17 million net income) with positive operating cash flow, but it still reported a small net loss for full-year 2025 and slipped back to a loss in Q1 2026. Profitability is at an early inflection rather than consistently established.